Small molecule biomarkers predictive of Chagas disease progression

Zongyuan Liu[1], Steffany Vucetich[2], Kelly DeToy[2], Gustavo Durán Saucedo[3], Manuela

Verastegui[4], Paula Carballo-Jimenez[5], Brandon N. Mercado-Saavedra[3], Freddy Tinajeros[5], Edith

S. Málaga-Machaca[4], Rachel Marcus[6], Robert H. Gilman[2], Natalie M. Bowman[7*], Laura-Isobel

McCall[1,8*]

1. Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, USA

2. Department of International Health, Johns Hopkins Bloomberg School of Public Health,

Baltimore, MD, USA

3. Instituto de Investigación de Medicina, Universidad Católica Boliviana San Pablo, Santa Cruz,

Bolivia

4. Infectious Diseases Research Laboratory, LID, Faculty of Sciences and Engineering,

Universidad Peruana Cayetano Heredia, Lima, Peru

5. IFHAD: Innovation For Health And Development, Prisma NGO, Lima, Perú

6. Medstar Union Memorial Hospital, Baltimore, MD, USA

7. Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC,

USA

8. Department of Chemistry & Biochemistry, San Diego State University, San Diego, CA, USA

* Correspondence to: Natalie M. Bowman (natalie_bowman@med.unc.edu; clinical patient

cohort) or Laura-Isobel McCall (lmccall@sdsu.edu; overall study design and metabolomics)

Abstract

Chagas disease (CD) is a neglected tropical disease caused by the parasitic protozoan *Trypanosoma cruzi*. However, only 20% to 30% of infected individuals will progress to severe symptomatic cardiac manifestations. Current treatments are benznidazole and nifurtimox, which are poorly tolerated regimens. Developing a biomarker to determine the likelihood of patient progression would be helpful for doctors to optimize patient treatment strategies. Such a biomarker would also benefit drug discovery efforts and clinical trials. In this study, we combined untargeted and targeted metabolomics to compare serum samples from *T. cruzi*-infected individuals who progressed to severe cardiac disease, versus infected individuals who remained at the same disease stage (non-progressors). We identified four unannotated biomarker candidates, which were validated in an independent cohort using both untargeted and targeted analysis techniques. Overall, our findings demonstrate that serum small molecules can predict CD progression, offering potential for clinical monitoring.

Keywords

Chagas disease; *Trypanosoma cruzi*; disease progression; biomarkers; metabolomics; mass spectrometry

Introduction

Chagas disease (CD), caused by *Trypanosoma cruzi* parasites, is a vector-borne illness with a wide geographic range, primarily endemic to rural areas but also found in urban settings across Mexico, Central America, and South America This neglected tropical disease is continually expanding its range and impact due to climate change and migration; with cases found as far as Japan [1]. If untreated, *T. cruzi* infection is lifelong and can be life-threatening. CD can result in various complications, including megaesophagus, megacolon, arrhythmias, apical aneurysms, congestive heart failure, thromboembolism, and sudden death. Among these, Chagas cardiomyopathy is the most severe manifestation of the disease. Up to 30% of chronically infected people develop cardiac complications, while 10% develop digestive, neurological, or mixed symptomatology [2].

The primary diagnosis method in chronic CD is serology [3]. PCR detection can only demonstrate failure to clear parasites, not treatment success, given its high rate of false negatives [4–6]. Given these limitations, there have been considerable efforts made to identify alternative markers of successful parasite clearance and/or disease progression. These strategies include detection of antibodies to specific parasite proteins or parasite glycotopes [7,8,9,10,11], host protein fragments [12,13], coagulation factors [14], or evaluation of immune cell types [15,16]. A critical limitation of all these approaches, however, is that they rely on parasite clearance as a measure of treatment success and prognosis. However, the BENEFIT clinical trial demonstrated that, when treatment is administered to patients with pre-existing cardiac abnormalities, parasite clearance is insufficient to prevent disease progression or mortality [17]. Therefore, biomarkers that only measure parasite clearance are insufficient to predict clinical outcomes.

Multiple protein biomarkers have been correlated with CD stage, though none yet have proven useful in a clinical context. IFN-γ is essential for the control of *T. cruzi* infection in experimental models. Serum from patients with chronic Chagasic cardiomyopathy had relatively high expression of IFN-γ compared to noncardiac or indeterminate CD patients [18,19]. A recent study found that differences in the levels of 44 host proteins correlated with clinical progression. Interestingly, while many of those proteins were immune-associated, several of them (ATP5IF1, B4GALT1, GMPR, ISM1, AGRP) were linked to human metabolism [20]. Other protein biomarkers of CD severity (TNFα, brain natriuretic peptide (BNP), or the MMP-2/MMP-9 ratio, for example), only differentiate between symptomatic and asymptomatic patients or between advanced and early stages of cardiomyopathy, and may not be able to predict disease progression in asymptomatic individuals [21–24,25]. BNP is a very nonspecific marker of congestive heart failure and is therefore unsuitable as an early biomarker [26,23].

Serum and urine metabolites have been identified as indicators of *T. cruzi* infection status in human subjects and mouse models [27,28,29]. The level of cardiac acylcarnitines and glycerophosphocholines were correlated with markers of cardiac inflammation and fibrosis [30]. Furthermore, the cardiac metabolome could be used to predict infection outcome in acute mouse models of infection [31]. A recent study showed that some metabolites could be restored by treatment with the antiparasitic nifurtimox [28]. However, studies of metabolites as biomarkers of CD progression are lacking, especially in humans. Therefore, we analyzed samples from a multiyear cohort of *T. cruzi*-infected Bolivians, comparing CD patients who showed cardiac disease progression, to patients who remained asymptomatic, and found four metabolites to be promising biomarker candidates. Two of these metabolites showed increased levels in infected progressors at baseline compared to non progressors, while the other two were decreased in infected

progressors.. Given the significant adverse effects of antiparasitic drugs and intermittent drug

shortages [32], biomarkers of disease progression could help target more effective screening and

interventions towards those who would benefit from them the most.

Results

Study participants

To explore potential metabolite biomarkers of progression to more severe cardiac disease

in patients chronically infected with *T. cruzi*, we studied four groups: infected progressors (N=37),

infected non-progressors (N=91), uninfected 'progressors' (patients with non Chagasic heart

failure ; N=3) and uninfected non-progressors (healthy controls; N=13) (see Methods). Infected

patients were monitored over 3 years. Patients that showed no symptoms, normal

electrocardiogram (EKG) and normal echocardiograms were defined as stage A. Patients who

showed no symptoms but had abnormal EKG fitting specific criteria were defined as stage B.

Patients showing systolic dysfunction in echocardiogram (EF < 50) were defined as stage C or D.

If a patient progressed from stage A to B or B to C/D during the study, they were classified as

progressors, while the non-progressors were those that remained at stage A or B. Importantly,

samples were collected from progressors prior to disease advancement, so that any metabolic

changes identified in this study can serve as prospective biomarkers of disease progression. The

uninfected progressors group was used to evaluate whether the observed metabolite changes were

specific to chagasic cardiomyopathy or also found in nonchagasic pathologies.

We matched patients from the infected progressor group and patients from the infected

non-progressor group by gender, initial disease stage and age difference smaller than 5 years (see

Methods). Patient serum samples were analyzed by HPLC-MS/MS for untargeted metabolomic

analysis as described in the methods section, using two different chromatography methods

(pHILIC and polar C18), and MS data acquisition in positive and negative mode. Samples were

from two separate shipments of different patients, serving as two separate cohorts.

Limited association of progressing vs non-progressing status and overall metabolome

In terms of the overall metabolite profile (both cohorts combined), as shown in **Figure 1**,

all four groups clustered with each other. There was no significant difference in overall

metabolome between groups in polar C18 datasets, except between infected non-progressors and

uninfected non-progressors in positive mode ($p=0.048$ and pseudo-F=2.128), reflecting the impact

of infection on the metabolome. For pHILIC chromatography in both polarities, there were

likewise significant differences in overall metabolome for infected non-progressors vs uninfected

non-progressors ($p=0.006$ and pseudo-F=3.815 for positive mode, $p=0.012$ and pseudo-F=3.920

for negative mode), as well as differences between infected progressors vs uninfected non-

progressors ($p=0.021$ and pseudo-F=2.905 for positive mode, $p=0.042$ and pseudo-F=2.987 for

negative mode) (**Table 1**).

Figure 1. Limited overall differences in serum metabolite profile between uninfected non-progressor group, uninfected progressor group, infected non-progressor group, and infected progressor group from pHILIC and polar C18 separation in both positive mode and negative mode data. All four groups showed overlap.

Table 1. Limited differences in overall metabolism between the four different patient groups. PERMANOVA p values with Benjamini-Hochberg FDR correction. Bold, FDR-corrected p<0.05.

datasets	group 1	group 2	p value	pseudo F
pHILIC in positive mode	infected non-progressors	infected progressors	0.3640	1.330964
	infected non-progressors	**uninfected non-progressors**	**0.0120**	**3.846872**
	infected non-progressors	uninfected progressors	0.8130	0.664337
	infected progressors	**uninfected non-progressors**	**0.0120**	**2.904537**
	infected progressors	uninfected progressors	0.8130	0.685083
	uninfected non-progressors	uninfected progressors	0.6285	1.021994
	infected non-progressors	infected progressors	0.941	0.586750

pHILIC in negative mode	**infected non-progressors**	**uninfected non-progressors**	**0.018**	**3.937563**
	infected non-progressors	uninfected progressors	0.941	0.590266
	infected progressors	**uninfected non-progressors**	**0.030**	**2.987234**
	infected progressors	uninfected progressors	0.941	0.442172
	uninfected non-progressors	uninfected progressors	0.648	1.113972
polar C18 in positive mode	infected non-progressors	infected progressors	0.526	1.129306
	infected non-progressors	**uninfected non-progressors**	**0.048**	**2.128310**
	infected non-progressors	uninfected progressors	0.931	0.741003
	infected progressors	uninfected non-progressors	0.117	1.707515
	infected progressors	uninfected progressors	0.931	0.642245
	uninfected non-progressors	uninfected progressors	0.931	0.674938
polar C18 in negative mode	infected non-progressors	infected progressors	0.4275	1.170979
	infected non-progressors	uninfected non-progressors	0.3480	1.528665
	infected non-progressors	uninfected progressors	0.4275	1.113128
	infected progressors	uninfected non-progressors	0.3570	1.364624
	infected progressors	uninfected progressors	0.4290	1.012039
	uninfected non-progressors	uninfected progressors	0.4290	1.037428

Interestingly, for negative mode pHILIC data, infected progressors were more divergent from infected non-progressors than from uninfected non-progressors in terms of overall metabolome. For the positive mode polar C18 dataset, the infected progressors vs uninfected non-progressors showed the largest difference compared to infected progressors vs infected non-

progressors and infected progressors vs uninfected progressors in terms of overall metabolome,

indicating that infected progressors have a distinct serum metabolite profile compared to infected

non-progressors and uninfected non-progressors. The smaller difference between infected

progressors and uninfected progressors in terms of overall metabolome suggests that progressed

heart disease could show similar predictive metabolite profiles, with the caveat that only few

uninfected progressor samples were available in this study. There were no significant differences

between inter-group overall metabolic distances in positive mode pHILIC and negative mode polar

C18 datasets (**Figure 2**).

Figure 2. PCoA distances between different progression groups. All cohorts, sexes and ages
combined. P values are calculated by Mann-Whitney U test, two-sided, FDR-corrected, *: 1.00e-
02 < p ≤ 5.00e-02, **: 1.00e-03 < p ≤ 1.00e-02, ***: 1.00e-04 < p ≤ 1.00e-03, ****: p ≤ 1.00e-04.
ns, non-significant.

Limited confounding impact of age and sex

We also assessed whether different sexes showed different metabolite profiles associated

with disease progression. However, as shown in **Figure S1**, we found that all four datasets showed

no differences in terms of overall metabolome between experimental groups in both male and

female subjects.

Samples were selected to have equal age representation and sex representation between

groups. However, we performed multi-parameter PERMANOVA to test the interaction between

age and sex, to know whether sex and age effects reduced our statistical power or masked effects

of disease on the metabolites. Positive mode pHILIC and polar C18 datasets showed a significant

effect of age but not sex. However, negative mode pHILIC showed a significant effect of sex and

age, and negative polar C18 showed no significant effect of sex or age (**Table 2**). Importantly, all

four datasets showed no significant interactions between disease progression status and gender or

age (**Table 2**, PERMANOVA $p > 0.05$). These results indicate that the different ages of the subjects

are impacting the metabolome, but not confounding our interpretation of disease outcomes, so we

chose to not subset the dataset by age or sex and analyze all samples jointly.

Table 2. p values of multi-parameter PERMANOVA for interaction between gender, age
and infection status. Bold, p<0.05.

datasets	statistical results	gender	age	CD status	gender & age	CD status & age	CD status & gender
positive pHILIC	R^2	0.011559	**0.016552**	**0.038838**	0.005335	0.016831	0.019426
	p value	0.062	**0.017**	**0.006**	0.659	0.792	0.567
negative pHILIC	R^2	**0.017923**	**0.023319**	**0.033940**	0.006735	0.014676	0.012115
	p value	**0.012**	**0.007**	**0.041**	0.375	0.869	0.963
positive polar C18	R^2	0.010340	**0.017939**	0.026836	0.007124	0.017459	0.017973
	p value	0.075	**0.005**	0.079	0.378	0.780	0.736
negative polar C18	R^2	0.010930	0.010042	0.026023	0.007260	0.018661	0.018322
	p value	0.055	0.102	0.102	0.375	0.687	0.714

Discovery of individual metabolites predictive of progression status

To enable biomarker discovery and validation in separate cohorts, we separated samples

based on shipments into two cohorts. Cohort 1 was used to discover candidate biomarkers, with

validation in cohort 2, and vice versa, using untargeted metabolomics data to discover candidates,

which were subsequently validated by targeted parallel reaction monitoring (PRM) analysis

(**Figure 3**).

Figure 3. Diagram of the cross-validation between different cohorts. For cohort 1, N=26 infected progressors, N=69 infected non-progressors, N=3 uninfected progressors, N=13 uninfected non-progressors. For cohort 2, N=11 infected progressors, N=22 infected non-progressors.

Our discovery significance cutoff was uncorrected two-sided Mann-Whitney-Wilcoxon

p<0.05 for infected progressors vs infected non-progressors. We made this choice to select the

broadest range of candidates in the inclusion list for targeted analysis and minimize false negatives.

Targeted analysis on the second cohort then serves as independent validation, to eliminate any

false positives. We then assessed if metabolites that met this significance criterion showed the

same direction of changes in both cohorts, with no significance cutoff. Lastly, we performed ROC

analysis, with AUC > 0.65 to filter this inclusion list for PRM analysis. However, in positive mode

polar C18 cohort 1 discovery analysis, following the AUC cutoff, no candidate remained. To

expand the inclusion list for targeted analysis, we therefore manually added four additional specific

m/z based on the literature on CD pathogenesis, for evaluation in the validation cohort.

Specifically, given our prior findings on impacts of infection on glycerophosphocholines and

purines [33], we manually selected *m/z* 482.361 (lysophosphocholine O-16:0), *m/z* 137.046

(hypoxanthine), *m/z* 348.07 (adenosine diphosphate) and *m/z* 269.088 (xanthosine) to expand the

inclusion list. We also included these four candidates for validation analysis in cohort 1 (**Table 3**).

Biomarker candidate validation

Discovered candidate biomarkers were then validated in the reciprocal patient cohort using

targeted analysis. Using this approach, we validated four biomarker candidates which showed

significant differences between infected progressors and infected non-progressors in the validation

cohort (**Table 3**). Two candidates came from the positive mode pHILIC dataset, and two from the

negative mode pHILIC dataset. As shown in **Figure 4** and **Figure 5**, *m/z* 547.436 RT (retention

time) 1.085 min from cohort 2 was validated by targeted analysis in cohort 1. *m/z* 540.411 RT 1.3

min from cohort 2 was validated by targeted analysis in cohort 1. *m/z* 295.14 RT 2.16 min and

m/z 493.39 RT 1.077 min, from negative mode pHILIC dataset in cohort 1 were validated by

targeted analysis in cohort 2. None of these metabolites had annotations.

Table 3. Candidate metabolite filtering and cross-validation. * means selection of   extra
candidates based on our current knowledge of CD, as described above.

cohort 1 discovery, cohort 2 validation				
	positive pHILIC	negative pHILIC	positive pC18	negative pC18
discovered in cohort 1	308	439	7	11
validated in cohort 2 (untargeted)	3	1	0	1
inclusion list for PRM	3	1	4*	1
PRM validation in cohort 2	0	0	0	0
cohort 2 discovery, cohort 1 validation				
	positive pHILIC	negative pHILIC	positive pC18	negative pC18
discovered in cohort 2	474	410	292	160
validated in cohort 1 (untargeted)	17	13	7	1
inclusion list for PRM	17	13	11*	1
PRM validation in cohort 1	2	2	0	0

Figure 4. Cross-validated biomarker candidates. (a) *m/z* 547.436 RT 1.085 min, from positive mode pHILIC dataset, initial discovery in cohort 2 (a1) and initial validation in cohort 1 (a2), secondary validation in cohort 1 (a3). (b) *m/z* 540.411 RT 1.3 min, from positive mode pHILIC dataset, initial discovery in cohort 2 (b1) and initial validation in cohort 1 (b2), secondary validation in cohort 1 (b3). (c) *m/z* 295.14 RT 2.16 min, from negative mode pHILIC dataset, initial discovery in cohort 1 (c1) and initial validation in cohort 2 (c2), secondary validation in cohort 2 (c3). (d) *m/z* 493.39 RT 1.077 min, from negative mode pHILIC dataset, initial discovery in cohort 1 (d1) and initial validation in cohort 2 (d2), secondary validation in cohort 2 (d3). All four metabolites showed significant differences between infected progressors and infected non-progressors. P values are calculated by Mann-Whitney U test, two-sided, no FDR-correction, *: 1.00e-02 < p ≤ 5.00e-02, **: 1.00e-03 < p ≤ 1.00e-02, ***: 1.00e-04 < p ≤ 1.00e-03, ****: p ≤ 1.00e-04.

Figure 5. Biomarker ROC curves. The AUC values for 547.436 RT 1.085 min and m/z 540.411 RT 1.3 min came from training in cohort 2 and predicted in cohort 1. The AUC values for m/z 295.14 RT 2.16 min and m/z 493.39 RT 1.077 min came from training in cohort 1 and predicted in cohort 2.

Discussion

The ideal biomarker of CD should reflect disease progression, so that doctors can optimize interventions. There is currently no consensus on treatment of asymptomatic adults. Current CDC guidelines recommend treating asymptomatic *T. cruzi*-positive individuals 50 years or younger; treatment is optional for patients over 50 years old due to the high risk of side effects [10]. The Pan American Health Organization (PAHO) recommends treatment in asymptomatic patients irrespective of age [34], whereas the Brazilian Society of Cardiology sets an age cutoff similar to the

CDC [35] . This age range includes over a quarter of CD patients [36,3738] and most of the CD mortality

[39]. 14% of adults treated with benznidazole, the preferred agent, will suspend treatment because of

adverse effects [40]. A biomarker of disease progression could enable patients to make informed

decisions with regards to the relative risks and benefits of treatment, enable assessment of

treatment success, or inform clinical trial design.

Given prior work showing changes in circulating metabolites with *T. cruzi* infection in

mouse models [29,41], their association with disease severity in mouse models [30,42], and infection-

associated metabolite changes in human CD patients[28], we hypothesized that metabolite levels in

the serum of *T. cruzi*-infected individuals could predict CD progression. Overall metabolite

profiles between all four groups (infected progressors, infected non-progressors, uninfected

progressors and uninfected non-progressors) were very similar. Given that our discovery analysis

was being followed by a validation cohort, we chose to use looser criteria by not using FDR

correction for p-values in the discovery cohort. This decision led to low validation rates (**Table 3**),

but nevertheless enabled the discovery and validation of four candidate biomarkers at the

individual metabolite level. We also chose not to a priori exclude the biomarker candidates that

also showed significant differences between uninfected progressor and uninfected non-

progressors, because CD can be differentiated from non-CD heart disease through other means

(e.g. PCR, serodiagnosis [3]).

One limitation for this project is patient comorbidities and behavioral differences that likely

increased variability. Multi-parameter PERMANOVA analysis showed that the different ages of

the subjects impact the metabolome, but did not confound our interpretation of disease outcomes

(**Table 2**). We therefore elected to analyse all samples jointly, without subsetting the dataset by

age or sex and for better statistical power given the limited sample numbers available. Likewise,

it is possible that some non-progressors will ultimately progress to symptomatic disease outside

this study's follow-up period, in which case our results may be interpreted as differentiating

between faster and slower progressors. Even given these limitations, we successfully validated

four biomarker candidates. *m/z* 547.436 RT 1.085 min and *m/z* 493.39 RT 1.077 min showed

decreased levels in infected progressors compared to infected non-progressors, while *m/z* 540.411

RT 1.3 min and *m/z* 295.14 RT 2.16 min showed increased level in infected progressors compared

to infected non-progressors. The lack of annotations for these biomarkers limits the biological

insight that can be derived from them. However, from a clinical implementation perspective,

annotations are not necessary for disease prediction. To enable cross-study assessment, we provide

m/z, retention time and MS/MS spectra, per the recommendations of the Metabolomics Standards

Initiative [43] (**Table S13).** Given the low parasite burden in chronic CD, these biomarkers are almost

certainly of host origin.

Further investigation in dogs and other animal models could be implemented to determine

whether these biomarkers are common in mammals or only specific to humans. Canine biomarkers

would be particularly useful given the high rates of CD in working dogs [44]. Assessment with a

larger sample size is necessary for further validation, particularly with regards to patient and

parasite genetic diversity. Evaluation of biomarker changes in response to treatment is also

necessary.

Conclusion

We have identified four metabolite biomarkers that are predictive of progression to more

severe cardiac CD. These biomarkers show promise for use in human cohorts, either in the context

of evaluation of new therapeutic modalities, to prioritize treatment when drug availability is

limited, or to increase treatment compliance in the highest-risk group.

Materials and methods

Study population

Serum samples were from the Johns Hopkins-Universidad Peruana Cayetano Heredia

Collaborated Studies Chagas disease biorepository, Johns Hopkins Institutional Review Board

(IRB) approval number IRB00007176. Initial sample collection was under Johns Hopkins

Institutional Review Board (IRB) approval number IRB00009799.

Samples were collected from Chagas disease patients and uninfected controls at the San

Juan de Dios Hospital, Santa Cruz, Bolivia (**Table 4**). As shown in **Table 5**, there were two

shipments from the study site, consisting of samples from different study participants. The first

shipment included all four groups but the second shipment only contained infected progressors

and infected non-progressors. The following staging criteria was used for determination of cardiac

progressors vs cardiac non progressors. Advanced stages C and D were determined by ejection

fraction (EF) on echocardiography. $40 < EF < 50$ were designated stage C, regardless of EKG

results. $EF \leq 40$ was designated stage D, regardless of EKG results. If $EF > 50$, then the EKG results

were used to guide staging A vs B. To be classified as stage B, patients must present with at least

one of the following conditions: arrhythmias (including Afib/flutter, premature ventricular

contractions (PVCs) or ventricular tachycardia), bradycardia (heart rate <50), blocks (including

any AV Block, right bundle branch block, left bundle branch block, left anterior fascicular block,

non-specific intraventricular conduction delay, or bi or tri-fascicular blocks), pathologic Q waves,

or paced rhythm. A normal EKG or any of the following abnormalities were determined to be stage

A: axis deviation, right ventricular hypertrophy/left ventricular hypertrophy, left atrial

enlargement/right atrial enlargement, low voltage, ST/T alterations, sinus tachycardia, long QT.

These criteria were developed to distinguish EKG changes specifically associated with Chagasic

cardiomyopathy as stage B.

Table 4. Number of subjects with sex and age information.

groups		gender		age			total
		male	female	20-40	40-60	60-80	
uninfected non-progressors	cohort 1	10	3	3	7	3	13
	cohort 2	0	0	0	0	0	0
uninfected progressors	cohort 1	1	2	1	1	1	3
	cohort 2	0	0	0	0	0	0
infected non-progressors	cohort 1	52	17	10	43	16	69
	cohort 2	12	10	1	9	12	22
infected progressors	cohort 1	17	9	2	14	10	26
	cohort 2	6	5	1	4	6	11

319   **Table 5.** Number of subjects by disease progression stage.

Groups		stage A	stage B	stage A to B	stage A to C/D	total
uninfected non-progressors	cohort 1	13	0	0	0	13
	cohort 2	0	0	0	0	0
uninfected progressors	cohort 1	0	0	3	0	3
	cohort 2	0	0	0	0	0
infected non-progressors	cohort 1	69	0	0	0	69
	cohort 2	22	0	0	0	22
infected progressors	cohort 1	0	0	25	1	26
	cohort 2	0	0	4	7	11

Serum sample preparation

Serum metabolites were extracted by adding equal volume of 100% methanol with 0.5 µM sulfachloropyridazine (Fisher Optima) as internal standard, vortexed for 15 seconds, followed by centrifugation at 14800 RPM for 15 minutes. The supernatant was collected into a 96-well plate, then dried down by a speedvac overnight, as recommended in Dunn et al [45]. Dried sample plates were stored at -80°C.

Untargeted LC-MS/MS data acquisition

Before LC-MS/MS instrumental analysis, dried extracts were resuspended with 80% acetonitrile (Fisher Optima; LC-MS grade), spiked with 2 µM sulfadimethoxine (Sigma-Aldrich) as internal standard. Data acquisition was performed under the control of XCalibur and Tune software (ThermoScientific). Five pooled quality controls were injected at run start with injection volume 2 µL, 3 µL, 4 µL, and 5 µL to ensure system equilibration. Data was then acquired in randomized order, with a blank followed by a pooled quality control every 12 injections. The injection volume for each sample was 5 µL.

A pHILIC LC column (SeQuant® ZIC®-pHILIC, 5 µm polymer, 150 x 2.1 mm) was used, and the column was kept at 40℃ during the run. Liquid chromatography was performed at 0.25 mL/min flow rate for 18 min. LC gradient was as follows, with mobile phase A (water with 20 mM ammonium acetate pH 9.4) and mobile phase B (acetonitrile): 0-10 min=90% B; 10-12 min=decrease to 30% B; 12-12.666 min=hold at 30% B; 12.666-18 min=increase to 90% B.

After the pHILIC LC-MS run, sample plates were dried down and resuspended with 100% water (Fisher Optima; LC-MS grade), spiked with 2 µM sulfadimethoxine (Sigma-Aldrich) as internal standard. A Kinetex polar C18 LC column (Phenomenex; 50×2.1 mm, 1.7 µM particle

size, 100 Å pore size) was used, and the column was kept at 40℃ during the run. Liquid

chromatography was performed at 0.5 mL/min flow rate for 12.5 min. LC gradient was as follows,

with mobile phase A (water + 0.1% formic acid) and mobile phase B (acetonitrile +0.1% formic

acid): 0-1 min=5% B; 1-9 min=increase to 100% B; 9-11 min=hold at 100% B; 11-11.5=decrease

to 5% B; and 11.5-12.5=5% B. Mass spectrometry data acquisition parameters were the same as

pHILIC LC-MS run. In all cases, mass spectrometry data acquisition parameters were as

previously published[33].

Targeted LC-MS/MS data acquisition

352   Resuspension procedure and LC columns were the same as for untargeted LC-MS/MS data

353   acquisition, but mass spectrometry data acquisition was performed in parallel reaction monitoring

354   (PRM) mode. Instrument parameters were the same as for untargeted LC-MS data acquisition.

355   Inclusion lists are in **Tables S5-12**.

Data analysis

For untargeted analysis, collected data were analyzed through MZmine (version 2.53)[46]

with parameters as in **Table S14**. Data were filtered to retain features that were present in at least

two samples and had MS2 spectra to enable annotation. Blank removal was performed with a

minimum threefold difference between the blank and serum samples required for a feature to be

retained. Total ion current (TIC) normalization to a constant sum of 1 was performed in Jupyter

Notebook using R (version 3.6.1). MZmine output files were uploaded and analyzed by Feature-

based molecular networking[47] in GNPS for annotation[33]. Annotations were retrieved using a script

developed in our laboratory [48]. Lipid annotations such as glycerophosphocholines,

glycerophosphoethanolamines and acylcarnitines were further confirmed by searching the LIPID

MAPS Structure Database (LMSD and COMPDB)[49,50]. Feature tables combined with metadata

were analyzed in QIIME2[51] for PCoA plot and distance analysis. Distances were compared using

Mann-Whitney-Wilcoxon test two-sided, FDR-corrected. PCoA plots were visualized in

EMPeror[52]. For further analysis, feature tables were filtered by the mass list which showed

significance between the infected progressed group vs infected non-progressed group. Jupyter

Notebook with Python (version 3.8.13) and R (version 3.6.1) were used for statistical analysis and

visualization.

To identify candidate biomarkers, we used Mann-Whitney-Wilcoxon test two-sided

without correction between infected progressors and infected non-progressors. This analysis

workflow minimizes false negatives. False positives are eliminated by analysis of an independent

set of patients, in the targeted PRM analysis workflow (see below). Fold changes were calculated

to confirm that the direction of changes between infected progressors and infected non-progressors

were consistent between the two cohorts. We use ROC analysis and an AUC cutoff of 0.65 to

further evaluate the performance of the candidate biomarkers between infected progressors and

infected non-progressors in the different cohorts. ROC curves were created using scikit-learn

(version 1.3.0).

For PRM data analysis, collected data from the validation cohorts were analyzed through

Skyline software (version 23.1) with parameters as in [27]. The exported peak areas were normalized

by the peak area of the internal standard (m/z 311.0801 for positive mode and m/z 309.0656 for

negative mode). Boxplot visualizations were made in Jupyter Notebook with Python (version

3.8.13) and R (version 3.6.1).

Data availability

The untargeted MS data generated in this study have been deposited in the MassIVE

database for positive mode pHILIC: (MSV000092754),

negative mode pHILIC (MSV000092756), positive mode polar C18 (MSV000092757), and

negative mode polar C18 (MSV000092758). Feature-based molecular networking for untargeted

MS data can be accessed at:

https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=ad84b5b572864898a733f159320bbd12

(positive mode pHILIC),

https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=7c725bc5bd23485dad48f5e3d6a5a84a

(negative mode pHILIC),

https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=73c7f72874d64fe78c9f97657df45bee

(positive mode polar C18),

https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=1e4c73cec97a4f09bbbd126da52a7262

(negative mode polar C18). The targeted MS data for PRM validation have been deposited in the

MassIVE database for positive mode pHILIC (MSV000093740), negative mode pHILIC

(MSV000093741), positive mode polar C18: (MSV000093742), and negative mode polar C18

(MSV000093743). Representative code has been deposited on GitHub, at

https://github.com/zyliu-OU/McCall-Lab/tree/main/05092023.

Author Contributions

L-I.M. designed the project. Z.L. performed metabolite extraction, LC-MS data acquisition and LC-MS data analysis. Z.L. drafted the initial manuscript, which was edited by L-I.M. with input from all authors. R.H.G. is the PI for the ongoing Bolivian cohort study which provided the samples. R.H.G. and N.M.B. participated in study design, data interpretation, and manuscript editing. K.D. and S.V. performed data management, cleaning, and staging for the samples. G.D.S., M.V., P.C.J., B.M.S., F.T., E.M. and R.M. collected samples and patient data.

Conflicts of interest

The authors have no conflict of interest to declare.

Supporting Information

Figure S1. PCoA distances between different progression groups for male and female participants. Table S1-S4. Annotation of differential metabolites. Table S5-S12. Skyline transition lists. Table S13. MS2 spectra information for cross-validated biomarker candidates. Table S14. MZmine data processing parameters table for all four datasets.

Acknowledgments

This project was supported by NIH award number R21AI156669. Samples were from the Johns Hopkins-Universidad Peruana Cayetano Heredia Collaborated Studies Chagas disease biorepository, with prior sample collection, clinical data collection and some salary support to R.H.G and N.M.B. supported by NIH award number R01AI107028. The content is solely the

responsibility of the authors and does not necessarily represent the official views of the National

Institutes of Health.

Abbreviations used

CD, Chagas disease;

HILIC, Hydrophilic interaction chromatography;

LC-MS/MS, liquid chromatography-tandem mass spectrometry;

PRM, parallel reaction monitoring;

RT, retention time

References

(1) Moncayo, A. Chagas Disease: Current Epidemiological Trends after the Interruption of

Vectorial and Transfusional Transmission in the Southern Cone Countries. *Mem. Inst.*

Oswaldo Cruz **2003**, *98* (5), 577–591.

(2) Pinazo, M.-J.; Thomas, M.-C.; Bustamante, J.; Almeida, I. C. de; Lopez, M.-C.; Gascon, J.

Biomarkers of Therapeutic Responses in Chronic Chagas Disease: State of the Art and

Future Perspectives. *Mem. Inst. Oswaldo Cruz* **2015**, *110* (3), 422–432.

(3) The Use of IgG Antibodies in Conventional and Non-Conventional Immunodiagnostic

Tests for Early Prognosis after Treatment of Chagas Disease. *J. Immunol. Methods* **2011**,

370 (1-2), 24–34.

(4) Russomando, G.; Almirón, M.; Candia, N.; Franco, L.; Sánchez, Z.; de Guillen, I.

[Implementation and Evaluation of a Locally Sustainable System of Prenatal Diagnosis to

Detect Cases of Congenital Chagas Disease in Endemic Areas of Paraguay]. *Rev. Soc. Bras.*

Med. Trop. **2005**, *38 Suppl 2*, 49–54.

(5)   Mora, M. C.; Negrette, O. S.; Marco, D.; Barrio, A.; Ciaccio, M.; Segura, M. A.;

Basombrío, M. A. EARLY DIAGNOSIS OF CONGENITAL TRYPANOSOMA CRUZI

INFECTION USING PCR, HEMOCULTURE, AND CAPILLARY CONCENTRATION,

AS COMPARED WITH DELAYED SEROLOGY. *J. Parasitol.* **2005**, *91* (6), 1468–1473.

(6)   Diez, C. N.; Manattini, S.; Zanuttini, J. C.; Bottasso, O.; Marcipar, I. The Value of

Molecular Studies for the Diagnosis of Congenital Chagas Disease in Northeastern

Argentina. *Am. J. Trop. Med. Hyg.* **2008**, *78* (4).

(7)   Krautz, G. M.; Galvão, L. M.; Cançado, J. R.; Guevara-Espinoza, A.; Ouaissi, A.; Krettli,

A. U. Use of a 24-Kilodalton Trypanosoma Cruzi Recombinant Protein to Monitor Cure of

Human Chagas' Disease. *J. Clin. Microbiol.* **1995**. https://doi.org/10.1128/jcm.33.8.2086-

2090.1995.

(8)   Meira, W. S. F.; Galvão, L. M. C.; Gontijo, E. D.; Machado-Coelho, G. L. L.; Norris, K. A.;

Chiari, E. Use of the Trypanosoma Cruzi Recombinant Complement Regulatory Protein To

Evaluate Therapeutic Efficacy Following Treatment of Chronic Chagasic Patients. *J. Clin.*

Microbiol. **2004**. https://doi.org/10.1128/jcm.42.2.707-712.2004.

(9)   Fernández-Villegas, A.; Pinazo, M. J.; Marañón, C.; Thomas, M. C.; Posada, E.; Carrilero,

B.; Segovia, M.; Gascon, J.; López, M. C. Short-Term Follow-up of Chagasic Patients after

Benznidazole Treatment Using Multiple Serological Markers. *BMC Infect. Dis.* **2011**, *11*

(1), 1–7.

(10)   Montoya, A. L.; Carvajal, E. G.; Ortega-Rodriguez, U.; Estevao, I. L.; Ashmus, R. A.;

Jankuru, S. R.; Portillo, S.; Ellis, C. C.; Knight, C. D.; Alonso-Padilla, J.; Izquierdo, L.;

Pinazo, M.-J.; Gascon, J.; Suarez, V.; Watts, D. M.; Malo, I. R.; Ramsey, J. M.; Alarcón De

Noya, B.; Noya, O.; Almeida, I. C.; Michael, K. A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease. *Molecules* **2022**, *27* (17). https://doi.org/10.3390/molecules27175714.

(11) Montoya, A. L.; Gil, E. R.; Heydemann, E. L.; Estevao, I. L.; Luna, B. E.; Ellis, C. C.; Jankuru, S. R.; Alarcón de Noya, B.; Noya, O.; Zago, M. P.; Almeida, I. C.; Michael, K. Specific Recognition of β-Galactofuranose-Containing Glycans of Synthetic Neoglycoproteins by Sera of Chronic Chagas Disease Patients. *Molecules* **2022**, *27* (2). https://doi.org/10.3390/molecules27020411.

(12) Santamaria, C.; Chatelain, E.; Jackson, Y.; Miao, Q.; Ward, B. J.; Chappuis, F.; Ndao, M. Serum Biomarkers Predictive of Cure in Chagas Disease Patients after Nifurtimox Treatment. *BMC Infect. Dis.* **2014**, *14* (1), 1–12.

(13) Ruiz-Lancheros, E.; Rasoolizadeh, A.; Chatelain, E.; Garcia-Bournissen, F.; Moroni, S.; Moscatelli, G.; Altcheh, J.; Ndao, M. Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole. *Open Forum Infect Dis* **2018**, *5* (11), ofy236.

(14) Pinazo, M.-J.; Posada, E. de J.; Izquierdo, L.; Tassies, D.; Marques, A.-F.; de Lazzari, E.; Aldasoro, E.; Muñoz, J.; Abras, A.; Tebar, S.; Gallego, M.; de Almeida, I. C.; Reverter, J.-C.; Gascon, J. Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. *PLoS Negl. Trop. Dis.* **2016**, *10* (1), e0004269.

(15) Bustamante, J. M.; Bixby, L. M.; Tarleton, R. L. Drug-Induced Cure Drives Conversion to a Stable and Protective CD8+ T Central Memory Response in Chronic Chagas Disease. *Nat. Med.* **2008**, *14* (5), 542–550.

494   (16) Cesar, G.; Natale, M. A.; Albareda, M. C.; Alvarez, M. G.; Lococo, B.; De Rissio, A. M.;

495   Fernandez, M.; Castro Eiro, M. D.; Bertocchi, G.; White, B. E.; Zabaleta, F.; Viotti, R.;

496   Tarleton, R. L.; Laucella, S. A. B-Cell Responses in Chronic Chagas Disease: Waning of

497   Trypanosoma Cruzi-Specific Antibody-Secreting Cells Following Successful Etiological

498   Treatment. *J. Infect. Dis.* **2023**, *227* (11), 1322–1332.

499   (17) Morillo, C. A.; Marin-Neto, J. A.; Avezum, A.; Sosa-Estani, S.; Rassi, A., Jr; Rosas, F.;

500   Villena, E.; Quiroz, R.; Bonilla, R.; Britto, C.; Guhl, F.; Velazquez, E.; Bonilla, L.; Meeks,

501   B.; Rao-Melacini, P.; Pogue, J.; Mattos, A.; Lazdins, J.; Rassi, A.; Connolly, S. J.; Yusuf,

502   S.; BENEFIT Investigators. Randomized Trial of Benznidazole for Chronic Chagas'

503   Cardiomyopathy. *N. Engl. J. Med.* **2015**, *373* (14), 1295–1306.

504   (18) Poveda, C.; Fresno, M.; Gironès, N.; Martins-Filho, O. A.; Ramírez, J. D.; Santi-Rocca, J.;

505   Marin-Neto, J. A.; Morillo, C. A.; Rosas, F.; Guhl, F. Cytokine Profiling in Chagas Disease:

506   Towards Understanding the Association with Infecting Trypanosoma Cruzi Discrete Typing

507   Units (A BENEFIT TRIAL Sub-Study). *PLoS One* **2014**, *9* (3), e91154.

508   (19) Sousa, G. R.; Gomes, J. A. S.; Fares, R. C. G.; Damásio, M. P. de S.; Chaves, A. T.;

509   Ferreira, K. S.; Nunes, M. C. P.; Medeiros, N. I.; Valente, V. A. A.; Corrêa-Oliveira, R.;

510   Rocha, M. O. da C. Plasma Cytokine Expression Is Associated with Cardiac Morbidity in

511   Chagas Disease. *PLoS One* **2014**, *9* (3), e87082.

512   (20) Sunderraj, A.; Cunha, L. M.; Avila, M.; Alexandria, S.; Ferreira, A. M.; de Oliveira-da

513   Silva, L. C.; Ribeiro, A. L. P.; Nunes, M. do C. P.; Sabino, E. C.; Landay, A.; Kalil, J.;

514   Chevillard, C.; Cunha-Neto, E.; Feinstein, M. J. Parasite DNA and Markers of Decreased

515   Immune Activation Associate Prospectively with Cardiac Functional Decline over 10 Years

516   among Trypanosoma Cruzi Seropositive Individuals in Brazil. *Int. J. Mol. Sci.* **2023**, *25* (1),

44.

(21) Ferreira, R. C.; Ianni, B. M.; Abel, L. C. J.; Buck, P.; Mady, C.; Kalil, J.; Cunha-Neto, E.

Increased Plasma Levels of Tumor Necrosis Factor-Alpha in

Asymptomatic/"indeterminate" and Chagas Disease Cardiomyopathy Patients. *Mem. Inst.*

Oswaldo Cruz **2003**, *98* (3), 407–411.

(22) Lima-Costa, M. F.; Cesar, C. C.; Peixoto, S. V.; Ribeiro, A. L. P. Plasma B-Type

Natriuretic Peptide as a Predictor of Mortality in Community-Dwelling Older Adults with

Chagas Disease: 10-Year Follow-up of the Bambui Cohort Study of Aging. *Am. J.*

Epidemiol. **2010**, *172* (2), 190–196.

(23) Okamoto, E. E.; Sherbuk, J. E.; Clark, E. H.; Marks, M. A.; Gandarilla, O.; Galdos-

Cardenas, G.; Vasquez-Villar, A.; Choi, J.; Crawford, T. C.; Do, R. Q.; Fernandez, A. B.;

Colanzi, R.; Flores-Franco, J. L.; Gilman, R. H.; Bern, C.; Chagas Disease Working Group

in Bolivia and Peru. Biomarkers in Trypanosoma Cruzi-Infected and Uninfected Individuals

with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia. *PLoS Negl. Trop. Dis.*

2014, *8* (10), e3227.

(24) Clark, E. H.; Marks, M. A.; Gilman, R. H.; Fernandez, A. B.; Crawford, T. C.; Samuels, A.

M.; Hidron, A. I.; Galdos-Cardenas, G.; Menacho-Mendez, G. S.; Bozo-Gutierrez, R. W.;

Martin, D. L.; Bern, C. Circulating Serum Markers and QRS Scar Score in Chagas

Cardiomyopathy. *Am. J. Trop. Med. Hyg.* **2015**, *92* (1), 39–44.

(25) Sherbuk, J. E.; Okamoto, E. E.; Marks, M. A.; Fortuny, E.; Clark, E. H.; Galdos-Cardenas,

G.; Vasquez-Villar, A.; Fernandez, A. B.; Crawford, T. C.; Do, R. Q.; Flores-Franco, J. L.;

Colanzi, R.; Gilman, R. H.; Bern, C. Biomarkers and Mortality in Severe Chagas

Cardiomyopathy. *Glob. Heart* **2015**, *10* (3), 173–180.

(26) Weber, M.; Hamm, C. Role of B-Type Natriuretic Peptide (BNP) and NT-proBNP in

Clinical Routine. *Heart* **2006**, *92* (6), 843–849.

(27) Dean, D. A.; Roach, J.; vonBargen, R. U.; Xiong, Y.; Kane, S. S.; Klechka, L.; Wheeler, K.;

Sandoval, M. J.; Lesani, M.; Hossain, E.; Katemauswa, M.; Schaefer, M.; Harris, M.;

Barron, S.; Liu, Z.; Pan, C.; McCall, L.-I. Persistent Biofluid Small-Molecule Alterations

Induced by Trypanosoma Cruzi Infection Are Not Restored by Parasite Elimination. *ACS*

Infectious Diseases **2023**. https://doi.org/10.1021/acsinfecdis.3c00261.

(28) Golizeh, M.; Nam, J.; Chatelain, E.; Jackson, Y.; Ohlund, L. B.; Rasoolizadeh, A.;

Camargo, F. V.; Mahrouche, L.; Furtos, A.; Sleno, L.; Ndao, M. New Metabolic Signature

for Chagas Disease Reveals Sex Steroid Perturbation in Humans and Mice. *SSRN*

Electronic Journal. https://doi.org/10.2139/ssrn.4050413.

(29) Lizardo, K.; Ayyappan, J. P.; Ganapathi, U.; Dutra, W. O.; Qiu, Y.; Weiss, L. M.;

Nagajyothi, J. F. Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic

Chagas Cardiomyopathy. *Dis. Markers* **2019**, *2019*, 4956016.

(30) Hoffman, K.; Liu, Z.; Hossain, E.; Bottazzi, M. E.; Hotez, P. J.; Jones, K. M.; McCall, L.-I.

Alterations to the Cardiac Metabolome Induced by Chronic Infection Relate to the Degree

of Cardiac Pathology. *ACS Infect Dis* **2021**, *7* (6), 1638–1649.

(31) McCall, L.-I.; Morton, J. T.; Bernatchez, J. A.; de Siqueira-Neto, J. L.; Knight, R.;

Dorrestein, P. C.; McKerrow, J. H. Mass Spectrometry-Based Chemical Cartography of a

Cardiac Parasitic Infection. *Anal. Chem.* **2017**, *89* (19), 10414–10421.

(32) Viotti, R.; Vigliano, C.; Lococo, B.; Alvarez, M. G.; Petti, M.; Bertocchi, G.; Armenti, A.

Side Effects of Benznidazole as Treatment in Chronic Chagas Disease: Fears and Realities.

Expert Rev. Anti. Infect. Ther. **2009**, *7* (2), 157–163.

(33) Liu, Z.; Ulrich vonBargen, R.; Kendricks, A. L.; Wheeler, K.; Leão, A. C.;

Sankaranarayanan, K.; Dean, D. A.; Kane, S. S.; Hossain, E.; Pollet, J.; Bottazzi, M. E.;

Hotez, P. J.; Jones, K. M.; McCall, L.-I. Localized Cardiac Small Molecule Trajectories and

Persistent Chemical Sequelae in Experimental Chagas Disease. *Nat. Commun.* **2023**, *14* (1),

1–22.

(34) Organización Panamericana de la Salud. [Synthesis of evidence: Guidance for the diagnosis

and treatment of Chagas diseaseSíntese de evidências: Guia de diagnóstico e tratamento da

doença de Chagas]. *Rev. Panam. Salud Publica* **2020**, *44*, e28.

(35) Marin-Neto, J. A.; Rassi, A., Jr; Oliveira, G. M. M.; Correia, L. C. L.; Ramos Júnior, A. N.;

Luquetti, A. O.; Hasslocher-Moreno, A. M.; Sousa, A. S. de; Paola, A. A. V. de; Sousa, A.

C. S.; Ribeiro, A. L. P.; Correia Filho, D.; Souza, D. do S. M. de; Cunha-Neto, E.; Ramires,

F. J. A.; Bacal, F.; Nunes, M. do C. P.; Martinelli Filho, M.; Scanavacca, M. I.; Saraiva, R.

M.; Oliveira Júnior, W. A. de; Lorga-Filho, A. M.; Guimarães, A. de J. B. de A.; Braga, A.

L. L.; Oliveira, A. S. de; Sarabanda, A. V. L.; Pinto, A. Y. das N.; Carmo, A. A. L. do;

Schmidt, A.; Costa, A. R. da; Ianni, B. M.; Markman Filho, B.; Rochitte, C. E.; Macêdo, C.

T.; Mady, C.; Chevillard, C.; Virgens, C. M. B. das; Castro, C. N. de; Britto, C. F. D. P. de

C.; Pisani, C.; Rassi, D. do C.; Sobral Filho, D. C.; Almeida, D. R. de; Bocchi, E. A.;

Mesquita, E. T.; Mendes, F. de S. N. S.; Gondim, F. T. P.; Silva, G. M. S. da; Peixoto, G. de

L.; Lima, G. G. de; Veloso, H. H.; Moreira, H. T.; Lopes, H. B.; Pinto, I. M. F.; Ferreira, J.

M. B. B.; Nunes, J. P. S.; Barreto-Filho, J. A. S.; Saraiva, J. F. K.; Lannes-Vieira, J.;

Oliveira, J. L. M.; Armaganijan, L. V.; Martins, L. C.; Sangenis, L. H. C.; Barbosa, M. P.

T.; Almeida-Santos, M. A.; Simões, M. V.; Yasuda, M. A. S.; Moreira, M. da C. V.;

Higuchi, M. de L.; Monteiro, M. R. de C. C.; Mediano, M. F. F.; Lima, M. M.; Oliveira, M.

T. de; Romano, M. M. D.; Araujo, N. N. S. L. de; Medeiros, P. de T. J.; Alves, R. V.;

Teixeira, R. A.; Pedrosa, R. C.; Aras Junior, R.; Torres, R. M.; Povoa, R. M. D. S.; Rassi, S.

G.; Alves, S. M. M.; Tavares, S. B. do N.; Palmeira, S. L.; Silva Júnior, T. L. da; Rodrigues,

T. da R.; Madrini Junior, V.; Brant, V. M. da C.; Dutra, W. O.; Dias, J. C. P. SBC Guideline

on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.

Arq. Bras. Cardiol. **2023**, *120* (6), e20230269.

(36) Herrador, Z.; Rivas, E.; Gherasim, A.; Gomez-Barroso, D.; García, J.; Benito, A.; Aparicio,

P. Using Hospital Discharge Database to Characterize Chagas Disease Evolution in Spain:

There Is a Need for a Systematic Approach towards Disease Detection and Control. *PLoS*

Negl. Trop. Dis. **2015**, *9* (4), e0003710.

(37) de Oliveira-Marques, D. S.; Bonametti, A. M.; Matsuo, T.; Gregori Junior, F. The

Epidemiologic Profile and Prevalence of Cardiopathy in Trypanosoma Cruzi Infected Blood

Donor Candidates, Londrina, Paraná, Brazil. *Rev. Inst. Med. Trop. Sao Paulo* **2005**, *47* (6),

321–326.

(38) Meymandi, S. K.; Forsyth, C. J.; Soverow, J.; Hernandez, S.; Sanchez, D.; Montgomery, S.

P.; Traina, M. Prevalence of Chagas Disease in the Latin American-Born Population of Los

Angeles. *Clin. Infect. Dis*. **2017**, *64* (9), 1182–1188.

(39) Herricks, J. R.; Hotez, P. J.; Wanga, V.; Coffeng, L. E.; Haagsma, J. A.; Basáñez, M.-G.;

Buckle, G.; Budke, C. M.; Carabin, H.; Fèvre, E. M.; Fürst, T.; Halasa, Y. A.; King, C. H.;

Murdoch, M. E.; Ramaiah, K. D.; Shepard, D. S.; Stolk, W. A.; Undurraga, E. A.;

Stanaway, J. D.; Naghavi, M.; Murray, C. J. L. The Global Burden of Disease Study 2013:

What Does It Mean for the NTDs? *PLoS Negl. Trop. Dis.* **2017**, *11* (8), e0005424.

(40) Crespillo-Andújar, C.; Venanzi-Rullo, E.; López-Vélez, R.; Monge-Maillo, B.; Norman, F.;

609 López-Polín, A.; Pérez-Molina, J. A. Safety Profile of Benznidazole in the Treatment of

610 Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review

611 with Meta-Analysis. *Drug Saf.* **2018**, *41* (11), 1035–1048.

612 (41) Gironès, N.; Carbajosa, S.; Guerrero, N. A.; Poveda, C.; Chillón-Marinas, C.; Fresno, M.

613 Global Metabolomic Profiling of Acute Myocarditis Caused by Trypanosoma Cruzi

614 Infection. *PLoS Negl. Trop. Dis.* **2014**, *8* (11), e3337.

615 (42) Hossain, E.; Khanam, S.; Dean, D. A.; Wu, C.; Lostracco-Johnson, S.; Thomas, D.; Kane,

616 S. S.; Parab, A. R.; Flores, K.; Katemauswa, M.; Gosmanov, C.; Hayes, S. E.; Zhang, Y.;

617 Li, D.; Woelfel-Monsivais, C.; Sankaranarayanan, K.; McCall, L.-I. Mapping of Host-

618 Parasite-Microbiome Interactions Reveals Metabolic Determinants of Tropism and

619 Tolerance in Chagas Disease. *Science Advances*. 2020.

620 https://doi.org/10.1126/sciadv.aaz2015.

621 (43) Sumner, L. W.; Amberg, A.; Barrett, D.; Beale, M. H.; Beger, R.; Daykin, C. A.; Fan, T.

622 W.-M.; Fiehn, O.; Goodacre, R.; Griffin, J. L.; Hankemeier, T.; Hardy, N.; Harnly, J.;

623 Higashi, R.; Kopka, J.; Lane, A. N.; Lindon, J. C.; Marriott, P.; Nicholls, A. W.; Reily, M.

624 D.; Thaden, J. J.; Viant, M. R. Proposed Minimum Reporting Standards for Chemical

625 Analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative

626 (MSI). *Metabolomics* **2007**, *3* (3), 211–221.

627 (44) Trypanosoma Cruzi Infection in Dogs along the US-Mexico Border: R0 Changes with

628 Vector Species Composition. *Epidemics* **2023**, *45*, 100723.

629 (45) Dunn, W. B.; Broadhurst, D.; Begley, P.; Zelena, E.; Francis-McIntyre, S.; Anderson, N.;

630 Brown, M.; Knowles, J. D.; Halsall, A.; Haselden, J. N.; Nicholls, A. W.; Wilson, I. D.;

631 Kell, D. B.; Goodacre, R. Procedures for Large-Scale Metabolic Profiling of Serum and

Plasma Using Gas Chromatography and Liquid Chromatography Coupled to Mass

Spectrometry. *Nat. Protoc.* **2011**, *6* (7), 1060–1083.

(46) Pluskal, T.; Castillo, S.; Villar-Briones, A.; Orešič, M. MZmine 2: Modular Framework for

Processing, Visualizing, and Analyzing Mass Spectrometry-Based Molecular Profile Data.

BMC Bioinformatics **2010**, *11* (1), 1–11.

(47) Nothias, L.-F.; Petras, D.; Schmid, R.; Dührkop, K.; Rainer, J.; Sarvepalli, A.; Protsyuk, I.;

Ernst, M.; Tsugawa, H.; Fleischauer, M.; Aicheler, F.; Aksenov, A. A.; Alka, O.; Allard, P.-

M.; Barsch, A.; Cachet, X.; Caraballo-Rodriguez, A. M.; Da Silva, R. R.; Dang, T.; Garg,

N.; Gauglitz, J. M.; Gurevich, A.; Isaac, G.; Jarmusch, A. K.; Kameník, Z.; Kang, K. B.;

Kessler, N.; Koester, I.; Korf, A.; Le Gouellec, A.; Ludwig, M.; Martin H, C.; McCall, L.-I.;

McSayles, J.; Meyer, S. W.; Mohimani, H.; Morsy, M.; Moyne, O.; Neumann, S.;

Neuweger, H.; Nguyen, N. H.; Nothias-Esposito, M.; Paolini, J.; Phelan, V. V.; Pluskal, T.;

Quinn, R. A.; Rogers, S.; Shrestha, B.; Tripathi, A.; van der Hooft, J. J. J.; Vargas, F.;

Weldon, K. C.; Witting, M.; Yang, H.; Zhang, Z.; Zubeil, F.; Kohlbacher, O.; Böcker, S.;

Alexandrov, T.; Bandeira, N.; Wang, M.; Dorrestein, P. C. Feature-Based Molecular

Networking in the GNPS Analysis Environment. *Nat. Methods* **2020**, *17* (9), 905–908.

(48) Lesani, M.; Gosmanov, C.; Paun, A.; Lewis, M. D.; McCall, L.-I. Impact of Visceral

Leishmaniasis on Local Organ Metabolism in Hamsters. *Metabolites* **2022**, *12* (9).

https://doi.org/10.3390/metabo12090802.

(49) Liebisch, G.; Fahy, E.; Aoki, J.; Dennis, E. A.; Durand, T.; Ejsing, C. S.; Fedorova, M.;

Feussner, I.; Griffiths, W. J.; Köfeler, H.; Merrill, A. H., Jr; Murphy, R. C.; O'Donnell, V.

B.; Oskolkova, O.; Subramaniam, S.; Wakelam, M. J. O.; Spener, F. Update on LIPID

MAPS Classification, Nomenclature, and Shorthand Notation for MS-Derived Lipid

Structures. *J. Lipid Res.* **2020**, *61* (12), 1539–1555.

(50) Liebisch, G.; Vizcaíno, J. A.; Köfeler, H.; Trötzmüller, M.; Griffiths, W. J.; Schmitz, G.;

Spener, F.; Wakelam, M. J. O. Shorthand Notation for Lipid Structures Derived from Mass

Spectrometry. *J. Lipid Res.* **2013**, *54* (6), 1523–1530.

(51) Bolyen, E.; Rideout, J. R.; Dillon, M. R.; Bokulich, N. A.; Abnet, C. C.; Al-Ghalith, G. A.;

Alexander, H.; Alm, E. J.; Arumugam, M.; Asnicar, F.; Bai, Y.; Bisanz, J. E.; Bittinger, K.;

Brejnrod, A.; Brislawn, C. J.; Brown, C. T.; Callahan, B. J.; Caraballo-Rodríguez, A. M.;

Chase, J.; Cope, E. K.; Da Silva, R.; Diener, C.; Dorrestein, P. C.; Douglas, G. M.; Durall,

D. M.; Duvallet, C.; Edwardson, C. F.; Ernst, M.; Estaki, M.; Fouquier, J.; Gauglitz, J. M.;

Gibbons, S. M.; Gibson, D. L.; Gonzalez, A.; Gorlick, K.; Guo, J.; Hillmann, B.; Holmes,

S.; Holste, H.; Huttenhower, C.; Huttley, G. A.; Janssen, S.; Jarmusch, A. K.; Jiang, L.;

Kaehler, B. D.; Kang, K. B.; Keefe, C. R.; Keim, P.; Kelley, S. T.; Knights, D.; Koester, I.;

Kosciolek, T.; Kreps, J.; Langille, M. G. I.; Lee, J.; Ley, R.; Liu, Y.-X.; Loftfield, E.;

Lozupone, C.; Maher, M.; Marotz, C.; Martin, B. D.; McDonald, D.; McIver, L. J.; Melnik,

A. V.; Metcalf, J. L.; Morgan, S. C.; Morton, J. T.; Naimey, A. T.; Navas-Molina, J. A.;

Nothias, L. F.; Orchanian, S. B.; Pearson, T.; Peoples, S. L.; Petras, D.; Preuss, M. L.;

Pruesse, E.; Rasmussen, L. B.; Rivers, A.; Robeson, M. S., 2nd; Rosenthal, P.; Segata, N.;

Shaffer, M.; Shiffer, A.; Sinha, R.; Song, S. J.; Spear, J. R.; Swafford, A. D.; Thompson, L.

R.; Torres, P. J.; Trinh, P.; Tripathi, A.; Turnbaugh, P. J.; Ul-Hasan, S.; van der Hooft, J. J.

J.; Vargas, F.; Vázquez-Baeza, Y.; Vogtmann, E.; von Hippel, M.; Walters, W.; Wan, Y.;

Wang, M.; Warren, J.; Weber, K. C.; Williamson, C. H. D.; Willis, A. D.; Xu, Z. Z.;

Zaneveld, J. R.; Zhang, Y.; Zhu, Q.; Knight, R.; Caporaso, J. G. Reproducible, Interactive,

Scalable and Extensible Microbiome Data Science Using QIIME 2. *Nat. Biotechnol.* **2019**,

37 (8), 852–857.

(52) Vázquez-Baeza, Y.; Pirrung, M.; Gonzalez, A.; Knight, R. EMPeror: A Tool for Visualizing

680   High-Throughput Microbial Community Data. *Gigascience* **2013**, *2* (1), 16.

681